Rinku General Medical Center
|
|
- みちしげ はにうだ
- 4 years ago
- Views:
Transcription
1 Rinku General Medical Center
2 Ann Intern Med. 1966; 64: CHOP J Clin Oncol. 1998; 16:
3 Febrile Neutropenia IDSA(Infectious Diseases Society of America) 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
4 a 60 b 21 a 1 b /mm3 X J Clin Oncol 2000 ; 28 : FN N72 N13 N20 N26 N13 11(855(2520(779(69 2(156(30 5(194(31 0 a 9(45 b 1(40 c a
5 (%) () MSSA ND MRSA NF-GNR A (35) 12(39) 8(26) B (59) 8(24) 6(18) C (66) 9(17) 9(17) D (68) 12(19) 8(13) Total
6 or or or or or + (38.3) 1 (500/mm 3 ) 2 IDSA(Infectious Diseases Society of America) 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer ~5
7 3~5 ( ) IDSA(Infectious Diseases Society of America) 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer 500/ / 23 3~5 3~5 B 5~7 IDSA(Infectious Diseases Society of America) 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
8 Randomized Trial of CFPM Monotherapy or CFPM in Combination with AMK as Empirical Therapy for FN. Clin Infect Dis. 2004; 39:S15 24 Table 5. Clinical response according to baseline neutrophil count among pts in the 2 treatment arms. No (%) of patients with response, by day after initiation of therapy and baseline neutrophil count Day 3 Day 7 Treatment arm, outcome CFPM Effective Not effective Subtotal CFPM+AMK Effective Not effective Subtotal All patients Effective Not effective Subtotal 500 cells/l 21 (27.6)a 21 ( 55 (72.4) 76 (100) 36 (45.0)e 36 ( 44 (55.0) 80 (100) 57 (36.5) 99 (63.5) 156 (100) 500 cells/l 10 (52.6)b 10 ( 9 (47.4) 19 (100) 7 (50.0)f 7 (50.0) 14 (100) 17 (51.5) 16 (48.5) 33 (100) Subtotal 31 (32.6) 64 (67.4) 95 (100) 43 (45.7) 51 (54.3) 94 (100) 74 (39.2) 115 (60.8) 189 (100) P values are as follows: a vs. b, P=0.038 ; a vs. e, P= cells/l 48 (63.2)c 28 (36.8) 76 (100) 60 (75.0)g 20 (25.0) 80 (100) 108 (70.1) 48 (29.9) 156 (100) 500 cells/l 13 (68.4)d 6 (31.6) 19 (100) 12 (85.7)h 2 (14.3) 14 (100) 25 (75.8) 8 (24.2) 33 (100) Subtotal 61 (64.2) 34 (35.8) 95 (100) 72 (76.6) 22 (23.4) 94 (100) 133 (78.8) 56 (21.2) 189 (100)
9 / 1 or 33 or Clinical Infectious Diseases 2004:39 (Supple1)
10 -D Clinical Infectious Diseases 2004:39; Clinical Infectious Diseases 2004:39;
11 ELISA) British Journal of Haematology :126: British Journal of Haematology :126:
12 B Clin Infect Dis. 2004; 39:S38 43
13 EX DNR VCR PSL L-Asp WBC / Blast 経過 1 Imatinib G-CSF Neutropenic fever CHF IPA (9/11) (9/24) (10/4) (10/9) (10/13) 肺アスペルギルス症 ( 画像 )
14 (WBC) AMPH-B 経過 2 Imatinib MCFG IPA (CRP) (10/15) (11/13) (12/10) (2/21) (3/12)
15 Rate,% OR(95% CI) P 3.47( ) ( ) 2.47( ) 1.59( ) 2.03( ) ( ) ( ) Rate,% OR(95% CI) P ( ) ( ) 3.47( ) ( ) 5.12( ) 2.09( ) 0.87( )
16 )
17
18
19
20 Clin Infect Dis. 2004; 39:S25 31
21
22 Clin Infect Dis. 1996; 23:
23 pg/ml
24 Rev Infect Dis Nov-Dec;12(6): retrospective / Clin Infect Dis May;26(5):
25 -12Hr 0
26 ClinicalCourse British Journal of Haematology 2004 :127:
27 British Journal of Haematology 2004 :127: Oncology Nursing Forum, 2004 ; 31: 4:
28
29 +
30 ESHAP 300mg 200mg~400mg 3g NSAIDS
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr NTT NTT
Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 121 23 7 7 IDSA 122 24 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr. 2012 7 2005 3 10 7 2011 6 2 NTT NTT 2011 6 Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS
More information要望番号 ;Ⅱ-24 未承認薬 適応外薬の要望 ( 別添様式 ) 1. 要望内容に関連する事項 要望者 ( 該当するものにチェックする ) 学会 ( 学会名 ; 特定非営利活動法人日本臨床腫瘍学会 ) 患者団体 ( 患者団体名 ; ) 個人 ( 氏名 ; ) 優先順位 8 位 ( 全 33 要望中
未承認薬 適応外薬の要望 ( 別添様式 ) 1. 要望内容に関連する事項 要望者 ( 該当するものにチェックする ) 学会 ( 学会名 ; 特定非営利活動法人日本臨床腫瘍学会 ) 患者団体 ( 患者団体名 ; ) 個人 ( 氏名 ; ) 優先順位 8 位 ( 全 33 要望中 ) 要望する医薬品 成 分 名 ( 一般名 ) 販 売 名 会 社 名 国内関連学会 amoxicillin-clabulanate
More information1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です
8. Page1 8. B 1 5) 6) 2099 2370 50 400 mg 19 (1) 1) (a) 78.9% 30/38 4 3 35.7% 5/14 71.4% 10/1485.7% 12/142 1 83.3% 5/63 2 1 1 1 8. Page2 (b) 2099 1897 82.4% 1562/1897 2 84.0% 1298/1545 3 2 80.4% 472/58779.0%
More informationTable 1.Distribution and number of cases with acute upper respiratory tract infections classified according to antimicrobial agents administered Table 2. Distribution of cases which were enrolled to set
More information要望番号 ;Ⅱ-183 未承認薬 適応外薬の要望 ( 別添様式 ) 1. 要望内容に関連する事項 要望者学会 ( 該当する ( 学会名 ; 日本感染症学会 ) ものにチェックする ) 患者団体 ( 患者団体名 ; ) 個人 ( 氏名 ; ) 優先順位 1 位 ( 全 8 要望中 ) 要望する医薬品
未承認薬 適応外薬の要望 ( 別添様式 ) 1. 要望内容に関連する事項 要望者学会 ( 該当する ( 学会名 ; 日本感染症学会 ) ものにチェックする ) 患者団体 ( 患者団体名 ; ) 個人 ( 氏名 ; ) 優先順位 1 位 ( 全 8 要望中 ) 要望する医薬品 要望内容 成分名 ( 一般名 ) 販売名 会社名 国内関連学会 未承認薬 適応 外薬の分類 ( 該当するものにチェックする )
More information37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
More informationE Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
More information400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
More informationuntitled
( ) - 1 - - 2 - 38% 26% A) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma 124 (J Clin Oncol 7: 126-131, 1989) 124 95 29 II 1 2,000mg/m 2 x 4 8g/m
More information! 1Munderl P et al. Survival and causes of death, 2 years after Introduction of antiretroviral therapy in Africa. XVI International AIDS Conference, 2006, Abstract THLB0208. 2Walensky RP et al. The
More information橡
TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1
More informationCHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
More informationTable 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
More informationuntitled
twatanab@oncoloplan.com http://www.oncoloplan.com I II - III IV Fig 3. Survival curves overall and according to response Bruzzi, P. et al. J Clin Oncol; 23:5117-5125 25 Copyright merican Society of Clinical
More informationuntitled
19 CSPOR CRC/2009.8.8-9 2009 8 8 ( ) - CSPOR CRC SEMINAR- twatanab@oncoloplan.com http://www.oncoloplan.com - Toru Watanabe MD - 2 Phase I: Dose Finding trial Phase II : Efficacy and Safety trial Phase
More information2
1 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234
More informationジャーナル4表紙
Jichi Medical University Journal of Nursing 7 3 4 55 63 75 a 83 93 97 3 9 5 9 3 5 7 97 5 9 6 ) 5) ) 36) 35 336 3 4 9 34 56 78 9 36 7 67 3 3 4 3 97 3 5 5 7 5 3 3 4 5 97 5 9 979 7 8564 887 97948 4 4 6
More informationuntitled
1) American College of Surgeons:Advanced Trauma Life Support Course Manual. American College of Surgeons 1997;103-112 24 2) American Society of Anesthesiologists Task Force:Practice guideline for blood
More informationuntitled
2303 16 2 9 1 14 5 31 (423) 1 (4), (6) C55H84ClN17O21S3 HCl (BLM-A2) 1487.47 11 2 1 4 104 2 14 5 31 [ ] ( ) ( ) 1. 15mg 30mg( ) 5 20mL 1 5mg( ) 2. 3 15mg 30mg( ) 5mL 1mg( ) 1mL 3. 5mg 15mg( ) 4. 1 2 1
More informationCHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection
More informationCandida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents
D 012 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents DATA : 1 DATA : 2 3 DATA : UNGITEC 1 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126)
More information終末期癌患者に対する 輸液治療の是非
3 A B NSAID D Case stories A B NSAID D Case stories A. IASP Task Force on Taxonomy WHO Collaborating Center for Palliative Cancer Care : Looking forward to cancer pain relief for all. CBC Oxford, Oxford,
More information26 1 : Self - reported Practices of Cancer Pain Management among Nurses in Tohoku University Hospital Hideyuki Hira
26 1 : 35 45 2017 1 2 2 2 2 2 2 2 2 1 1 2 Self - reported Practices of Cancer Pain Management among Nurses in Tohoku University Hospital Hideyuki Hirayama 1, Yoko Nakajo 2, Akemi Saito 2, Rie Hatakeyama
More informationVOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
More informationFig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl) oxy]-14-ethyl-12,
More information112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6 7 B 2 NTT 2012 6
Apr. 2013 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 111 53 8 8 1. Ph-ALL Liposomal amphotericin B 1 2. CBT MCFG L-AMBAML 2 112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon
June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
More informationVOL. 21 NO. 2 CHEMOTHERAPY 395
394 CHEMOTHERAPY MAR. 1973 VOL. 21 NO. 2 CHEMOTHERAPY 395 396 CHEMOTHERAPY MAR. 1973 VOL. 21 NO. 2 CHEMOTHERAPY 397 398 CHEMOTHERAPY MAR. 1973 VOL. 2 1 NO. 2 CHEMOTHERAPY 399 400 CHEMOTHERAPY MAR. 1973
More informationCHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
More informationKey words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba
More informationCHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
More information32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
More information第79回_プログラム.indd
Regulation of ghrelin signaling by a leptin-induced gene, negative regulatory element-binding protein, in the hypothalamic neurons. Phase I clinical trial using peptide vaccine for human vascular endothelial
More information<30332D D8CB492982D FC95E490E690B62D8FAC8FBC96BE90E690B62E706466>
A questionnaire survey on the use of placebo in clinical practice by nurses in Japan 1 1 2 2 1 4 1964 5, 6 1998 GCP 1 School of Nursing, Faculty of Medicine, Toho University 2Faculty of Medical Technology,
More informationSBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
More information広島県獣医学会雑誌24号.indd
1 1 Study on the effects of dexamethasone administration in acute coccidiosis accompanied by bloody stools TOMOYASU KUROSE Shoubara Veterinary Clinical Center, P. F. A. M. A. A -1-, Nishihonmachi, Shoubara,
More informationKey words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S. Table 1. Clinical summary of acute uncomplicated cystitis patients treated with 7432-S UTI : Criteria by the
More informationorororor oror CINAHL breast cancerhormonal therapyorendocrine therapyortamoxifenorgoserelinside effectorsymptomexperien
72017 3 資料 内分泌療法を受けている乳がん患者の苦痛体験に関する文献検討 A Literature Review regarding Distress Experienced by Breast Cancer Patients Undergoing Endocrine Therapy 四方文子 1), 鈴木久美 2) Ayako Shikata 1),Kumi Suzuki 2) キーワード
More information1) i) Barber, M. et al.: Brit. Med J, 2, 565, 19'49. ii) Barber, M.F.G. J. Hayhoe and J. E. M. Whithead: Lancet, 1120 `1125, 1949.-2) Bergey: Bergey's Manual of Determinative Bacteriology 7 th Ed: (1958).-3)
More informationVOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
More informationGB 3rd edition final.ppt
Complementary and Alternative Medicine (National Center for Complementary and Alternative Medicine; NCCAM) Complementary and alternative medicine is a group of diverse medical and health care systems,
More information20mg #tr#5*xlj lffin&+'.':, t) r+'z)vt '+D#J Centers for Medicare & Medicaid Sewices Garden AS et al. Preliminary results ofradiation Therapy Oncology Group 97-03: a randomized phase II trial of
More information食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
More informationFig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
More information未承認薬 適応外薬の要望に対する企業見解 ( 別添様式 ) 1. 要望内容に関連する事項 会社名要望された医薬品要望内容 グラクソ スミスクライン株式会社 要望番号 Ⅱ-24 成 分 名 アモキシシリン (AMPC) 水和物 クラブラン酸 ( 一般名 ) (CVA) カリウム オーグメンチン配合錠
未承認薬 適応外薬の要望に対する企業見解 ( 別添様式 ) 1. 要望内容に関連する事項 会社名要望された医薬品要望内容 グラクソ スミスクライン株式会社 要望番号 Ⅱ-24 成 分 名 アモキシシリン (AMPC) 水和物 クラブラン酸 ( 一般名 ) (CVA) カリウム オーグメンチン配合錠 125SS 販 売 名 (AMPC 125 mg/cva 62.5 mg) 同配合錠 250RS (AMPC
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr non-albicans 4 non-albicans C. glabrata, C. parapsilosis, C. tropicalis, C. krusei 4 C. guil
Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 111 13 B ACTIONs Bundle ACTIONs Bundle 2009 7 ACTIONs Bundle ACTIONs project Appropriate Candidal Treatment, Implementation Of Nonneutropenic strategies
More informationCHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
More information橡ボーダーライン.PDF
1 ( ) ( ) 2 3 4 ( ) 5 6 7 8 9 10 11 12 13 14 ( ) 15 16 17 18 19 20 ( ) 21 22 23 24 ( ) 25 26 27 28 29 30 ( ) 31 To be or not to be 32 33 34 35 36 37 38 ( ) 39 40 41 42 43 44 45 46 47 48 ( ) 49 50 51 52
More information051
June THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 295( 83 ) NTT 1. 2. 3. 4. CHOP-R 5. DNA 1 296( 84 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June 3 1 2003 10 4 1 NTT June THE JAPANESE JOURNAL OF ANTIBIOTICS
More informationuntitled
20 2 14 18 10 16 1 1.0mg 0.035mg 2 1 20 2 14 18 10 16 1 1 1 52 1 1 21 7 28 1 29 2 1 20 1 24 18 10 16 1 1 21 7 28 1 29 1 NET 1.0mg EE 0.035mg *NET *NET 1999 2007 *NET *NET 88 NSAIDs GnRH GnRH NSAIDs 20
More informationPubMed 1. CD-ROM MEDLINE MeSH PubMed 2. Automatic Term Mapping MeSH 3. Related Article 1 1. 2. MeSH Browser MeSH PreMEDLINE MeSH -2-
PubMed MEDLINE NLM 1879 Index Medicus 1960 MEDLARS Medical Literature Analysis and Retrieval System 1970 MEDLINE MEDlars online 1966 70 4,000 170 PubMed MEDLINE NLM National Center for Biotechnology Information
More informationTable 1 Diseases and isolated sources of 59 strains of S. pneumoniae in children Fig. 1 Susceptibility of penicillin-g for S. pneumoniae
Key words: penicillin insensitive and resistant pneumococcus Table 1 Diseases and isolated sources of 59 strains of S. pneumoniae in children Fig. 1 Susceptibility of penicillin-g for S. pneumoniae 小 児
More information★索引.indb
S 703 S 704 S 705 S 706 S 707 S 708 S 709 S 710 S 711 S 712 S 713 S 714 S 715 S 716 S 717 S 718 20 4 15 Japanese Journal of Medical Ultrasonics 35 101 0063 2 23 1 6 F The Japan Society of Ultrasonics in
More information1) Kojima H: Culture of ejaculate for Neisseria gonorrhoeae, 1st Serually Transmitted Diseases World Congress, San Juan, 11. 19, 1981. 9) Kojima H, Mori C: Clinical studies on Conococcal and Chlamydial
More information本文.indd
CQ ACC/AHA PECO PatientExposure Comparison OutcomePECO low-density lipoprotein cholesterol LDL C cholesterol cholesterol intensive OR agressive CQ target LDL C PubMed Systematic Reviews Clinical Study
More informationMV X 5 6 Common Terminology Criteria for Adverse Events Grade 1 Grade Gy 16 QOL QOL 5 6 7, 8 9, VOL.3 NO
乳がん患者の放射線皮膚炎に対するスキンケアの指導の実際 がん放射線療法看護認定看護師とがん放射線治療に携わる看護師との比較 Educating practice of skin care for radiodermatitis of breast cancer patients: Comparison of the nurses with certified nurse in radiation therapy
More information1) University Group Diabetes Program: A study of hypoglycemic agents on vascular complica- in patients with adult-onset tions diabetes. I. Design, methods and baseline results. Diabetes 19 (suppl. 2):
More informationスライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
More information【知事入れ版】270804_鳥取県人口ビジョン素案
7 6 5 4 3 2 1 65 1564 14 192 193 194 195 196 197 198 199 2 21 22 23 24 1.65 1,4 1.6 1,2 1.55 1, 1.45 6 1.5 8 1.4 4 1.35 1.3 2 27 28 29 21 211 212 213 214 6 5 4 3 2 1 213 218 223 228 233 238 243 248 253
More informationVENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
More information09Ł\”ƒ-Š€Ł\”ƒ
S A I U N C O N T E N T S ! " # $ % SAIUN1 S A I U N TOPICS from Ward 2SAIUN from Day Care Center from Occupational Therapy Center SAIUN3 S A I U N from Home Visit Nursing Center 4SAIUN SAIUN5 S A I U
More informationuntitled
19 11 13 300 18 3 31 1300mg 4 6 C 15 H 22 FN 3 O 6 359.35 + -1-5--β-D--5--1,2--2- -4- 19 11 13 300 18 3 31 A B B A 30 1 2 21 7 1 1 1.31m 2 900mg 1.31m 2 1.64m 2 1,200mg 1.64m 2 1,500mg B 30 1 2 14 7 1
More informationSARS HIV/AIDS n = 672; % 5% 2% 8% 16% 43% 20%
SARS HIV/AIDS n = 672; 20074 20108 6% 5% 2% 8% 16% 43% 20% 1999 2008 HIV/AIDS B A 0% 50% 100% 1049 552 17 186 867 431 739 3847 332 7556 102 2420 3648 449 802 2709 31774 1286 13651 1611 207 95 8 162 667
More informationCHEMOTHERAPY FEB Table 1 Background of volunteers
CHEMOTHERAPY FEB. 1985 Table 1 Background of volunteers Table 3 Reproducibility of saisomicln In the EIA and the RIA Fig.1 Comparison of the EIA with the RIA or bioassay of sisomicin Table 4 Blood levels
More informationJournal Club 2017/05/30 Tomohiro Matsumoto PGY-2
Journal Club 2017/05/30 Tomohiro Matsumoto PGY-2 本 の論 March 21, 2017 2 Introduc)on 3 : (CIN) 3 25% 44µmol/L(0.5mg/dL) CIN 4 European Society of Urogenital Radiology. ESUR guidelines on contrast media,
More informationThe nursing practices nurses consider important in the tertiary emergency rooms Kanako Honda'', Chizuko Miyake'', Midori Yao", Mikiko Kurushima", Kumiko Toyoda4 "The University of Shiga Prefecture, "Osaka
More information) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Toky
2.7 2.7.5 1) 199846410-437 2) UTI ( )UTI ( 3 )Chemotherapy (Tokyo) 1986 34408-441 3) () 199745762-778 4) 1992 5) 199543 6) Chemotherapy (Tokyo) 199139687-689 7) Imipenem/Cilastatin sodium (MK-0787/MK-0791)
More informationA A
3 A B C A A 2 5 1 62 A 1 1 2 63 3 1 A proven invasive fungal diseases 1 2 3 BAL 24 : Fusarium spp. 4 2 : Candida Trichosporon B probable invasive fungal diseases Cpossible invasive fungal diseases 5 1
More information2
1 2 3 15 4 1 15 1 31 3 15 1 162 272 CPA 46 28 CPA 1 CPA 4 CPA 5 a. ( ) ACLS 15 5 17 b. 1 12 c. 25 29 6 7 8 CPA CPA 1 CPA Randomized Controlled Trial, RCT RCT CPA CPA 1 Dr 9 CPA CPA 15 4 1 15 1 31 CPA CPA
More information化学療法
第 60 回 医 療 者 がん 研 修 会 2015/9/17 もっと 知 りたい 膀 胱 癌 治 療 尿 管 癌 膀 胱 癌 の 化 学 療 法 広 島 市 立 広 島 市 民 病 院 泌 尿 器 科 副 部 長 弓 狩 一 晃 泌 尿 器 科 での 化 学 療 法 経 尿 道 的 投 与 経 静 脈 動 脈 的 投 与 膀 胱 癌 治 療 1 表 在 癌 経 尿 道 的 膀 胱 腫 瘍 切 除
More information日本化学療法学会雑誌第65巻第4号
Mycoplasma pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae Key words Mycoplasma pneumoniae Mycoplasma pneumoniae M. pneumoniae I M. pneumoniae M. pneumoniae M. pneumoniae
More information01.12期・井須英次1.doc
Forum 21 Forum 21 Forum 21 Forum 21 Forum 21 Forum 21 Forum 21 Forum 21 Forum 21 Forum 21 Forum 21 21 Forum 21 Forum 21 Forum 21 Forum 21 21 Forum 21 21 Forum 21 Forum 21 Forum 21 Forum 21 Forum 21 Forum
More information1.3期・井上健0.doc
Forum 21 Forum 21 Forum 21 Forum 21 Forum 21 Forum 21 Forum 21 Forum 21 Forum 21 Forum 21 Forum 21 Forum 21 Forum 21 10 14 8 6.5 2 37 3 10 30 100 21,002 12 9,401 56 2 11 5 ( ) 231011 22.8 21.016.815.715.214.314.713.310.610.8
More informationTitle 歯性病巣の関連する皮膚疾患におけるビオチンの効用 Author(s) 高橋, 愼一 ; 川島, 淳子 ; 森本, 光明 ; 山根, 源之 Journal, (): - URL Right Posted at the Inst
Title 歯性病巣の関連する皮膚疾患におけるビオチンの効用 Author(s) 高橋, 愼一 ; 川島, 淳子 ; 森本, 光明 ; 山根, 源之 Journal, (): - URL http://hdl.handle.net/10130/526 Right Posted at the Institutional Resources for Unique Colle Available from
More informationJHN Journal Club 手稲渓仁会病院
JHOSPITALIST network GUIDE-IT trial; The Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure multicentre randomised clinical trial 20171010 1 70 (EF 30%), (PCI), (HbA1c
More information表 参照文献 ( 文献 ). 185, Expert Nurse. 1211, suppl, , CNS 2000, , , , 4
研究報告 がん看護専門看護師のコンサルテーション * についての概念分析 要旨 Walker Avant2005 CNS Key words はじめに 1996 2012 3 10 795 Certified Nurse SpecialistCNSCNS 327 1 CNS 2 CNS 3 4 5 6 CNS CNS 方法 Walker Avant 7 2012 8 1 2013 2 27 連絡先
More information日本化学療法学会雑誌第66巻第2号
173 Table 1.Detection rates of Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Ureaplasma urealyticum, Haemophilus influenzae and adenovirus from male urethritis in Urethritis No.
More information1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
More informationCore Ethics Vol. : - NICU : : - A B C D
Core Ethics Vol.,NMR...... Core Ethics Vol. : - NICU : : - A B C D b: Duff and Campbell A B C: D : a B C b Core Ethics Vol. : -, : C D :.. D.. bd D CD AB CD : Duff C b C B : Core Ethics Vol. C D B A D
More informationsick contact1l
Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5
More information_’£”R‡Ù‡©
29 31 38 2008 31 1) 2) 2) 3) 2) 1) 2008 302008 12 Activities of Daily Living ADL ADL 42 ADL ADL 1990 QOL Quality of Life QOL 1 QOL // 2 Activity of Daily Living ADL Performance Status PS ADL 3 1) 2) 3)
More informationPowerPoint プレゼンテーション
* ** 117,320 70,293 109,140 49,830 93,402 45,744 60,986 31,875 47,318 28,829 45,367 18,186 29,025 12,838 27,822 11,970 20,734 10,823 19,994 10,336 * 2007 ** 2011 65% 25% 9 DNA P53, ATM G1 S G2 G1 M 1
More informationFig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly notified cases of all fo
Kekkaku Vol. 79, No. 1: 17-24, 2004 17 (Received 21 Aug. 2003/Accepted 18 Nov. 2003) Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly
More informationJA2008
A1 1 10 vs 3 2 1 3 2 0 3 2 10 2 0 0 2 1 0 3 A2 3 11 vs 0 4 4 0 0 0 0 0 3 6 0 1 4 x 11 A3 5 4 vs 5 6 5 1 0 0 3 0 4 6 0 0 1 0 4 5 A4 7 11 vs 2 8 8 2 0 0 0 0 2 7 2 7 0 2 x 11 A5 9 5 vs 3 10 9 4 0 1 0 0 5
More informationPhase II clinical trials for patients with cancer
II II I 1 I III 14 20 14 20 14 0.05 14 20 1 10 25 20-80 100-200 95 CI (π B π A ) 1.96 [π A (1 π A )/n A + π B (1 π B )/n B ] π A = probability of response rate by treatment A π B = probability of response
More informationスライド 1
1 2006 msv 2 2011 3 CT 2011 10mSv 10 40mSv 4 2012 217mSv 5 (CT) 2012 50 60mSv 6 2012 510mSv BRCA25 310 10mSv3% BRCA60-280% 3 5m Sv 1m Sv 12% . http://www.rea.or.jp/ire/pdf/report4.pdf 1.10 20 SMR 1.00
More informationRX501NC_LTE Mobile Router取説.indb
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 1 2 3 4 5 6 7 8 19 20 21 22 1 1 23 1 24 25 1 1 26 A 1 B C 27 D 1 E F 28 1 29 1 A A 30 31 2 A B C D E F 32 G 2 H A B C D 33 E 2 F 34 A B C D 2 E 35 2 A B C D 36
More informationVOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence
More information